Our results found that the expression levels of PLXNB1 and GJA1 based on Braak NFT stages were significant, suggesting that these genes may be involved in AD pathogenesis and have a high potential for the development of AD biomarkers and target drugs. This evidence concerns the gene PLXNB1 and Alzheimer disease.